Angiodynamics (ANGO) Depreciation & Amortization (CF) (2010 - 2026)

Angiodynamics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 11.52% year-over-year to $5.6 million; the trailing twelve-month figure through Feb 2026 stood at $23.2 million (down 13.41% YoY), and the FY2025 full-year result was $25.8 million, down 6.9% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $5.6 million, down from $5.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $7.8 million in Q1 2023, with the low at $5.6 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $6.9 million across 5 years, with a median of $6.8 million in 2024.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) rose 17.52% — and 2025, when it slipped 16.26%.
• Angiodynamics' Depreciation & Amortization (CF) stood at $7.8 million in 2022, then slipped by 14.49% to $6.7 million in 2023, then grew by 2.66% to $6.9 million in 2024, then slipped by 16.26% to $5.7 million in 2025, then slipped by 2.71% to $5.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $5.6 million (Q1 2026), $5.7 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.